ARTICLE | Company News
GlaxoSmithKline sales and marketing update
January 20, 2003 8:00 AM UTC
GSK launched in the U.S. its Avodart dutasteride second-generation 5 alpha-reductase inhibitor to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ...